Publication:
Venous thromboembolism in pediatric patients with acute lymphoblastic leukemia under chemotherapy treatment. Risk factors and usefulness of thromboprophylaxis. Results of LAL-SEHOP-PETHEMA-2013.

dc.contributor.authorRuiz-Llobet, Anna
dc.contributor.authorGassiot, Susanna
dc.contributor.authorSarrate, Edurne
dc.contributor.authorZubicaray, Josune
dc.contributor.authorDapena, José Luis
dc.contributor.authorRives, Susana
dc.contributor.authorSevilla, Julián
dc.contributor.authorMenárguez López, Ángela
dc.contributor.authorPanesso Romero, Melissa
dc.contributor.authorMontoya, Catalina
dc.contributor.authorVagace, José Manuel
dc.contributor.authorMolina Hurtado, José Ramón
dc.contributor.authorGarcía-Morín, Marina
dc.contributor.authorGarcía Abós, Miriam
dc.contributor.authorMendoza Sánchez, María Carmen
dc.contributor.authorLendínez, Francisco
dc.contributor.authorPalomo Moraleda, Pilar
dc.contributor.authorTallón, María
dc.contributor.authorGonzález, Berta
dc.contributor.authorUrrutia, Emilia
dc.contributor.authorSerna, José Vicente
dc.contributor.authorPeláez Pleguezuelos, Irene
dc.contributor.authorMartínez Merino, Marta
dc.contributor.authorRamos Elbal, Eduardo
dc.contributor.authorOrellana, Elena
dc.contributor.authorBenítez Muñoz, Helga
dc.contributor.authorBerrueco, Rubén
dc.date.accessioned2023-05-03T13:29:28Z
dc.date.available2023-05-03T13:29:28Z
dc.date.issued2022-03-27
dc.description.abstractSymptomatic venous thromboembolism (VTE) is diagnosed in 3%-14% of patients during pediatric acute lymphoblastic leukemia (ALL) therapy. There are well-known risk factors, but the role of others as inherited thrombophilia is still controversial. Prophylaxis with low molecular weight heparin (LMWH) has been described, but its use is not globally accepted. A retrospective multicentric study in ALL patients 1-18 years old following SEHOP-PETHEMA-2013 treatment guideline was performed to evaluate VTE rate, anticoagulant treatment, outcome, risk factors, and safety and usefulness of LMWH administration as primary thromboprophylaxis in children with inherited thrombophilia. A total of 652 patients were included in the study. VTE incidence was 8.7%. Most of the cases occurred during induction therapy associated with central venous catheter. Univariant analysis showed that family history of thrombosis, presence of mediastinal mass, high-risk treatment group, and inherited thrombophilia were statistically significant risk factors. LMWH administration seemed to decrease VTE rate in patients with inherited thrombophilia and those with T-cell ALL phenotype. Most of the VTE cases occurred in patients without inherited thrombophilia, but when it is present, the VTE risk is higher. LMWH administration was useful to decrease VTE in these patients.
dc.identifier.doi10.1111/jth.15699
dc.identifier.essn1538-7836
dc.identifier.pmid35289066
dc.identifier.unpaywallURLhttp://www.jthjournal.org/article/S1538783622001945/pdf
dc.identifier.urihttp://hdl.handle.net/10668/20003
dc.issue.number6
dc.journal.titleJournal of thrombosis and haemostasis : JTH
dc.journal.titleabbreviationJ Thromb Haemost
dc.language.isoen
dc.organizationHospital Torrecárdenas
dc.organizationHospital Universitario Reina Sofía
dc.organizationHospital Universitario Virgen de las Nieves
dc.organizationHospital Universitario Virgen de las Nieves
dc.organizationHospital Universitario de Jaén
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationHospital Universitario Virgen Macarena
dc.organizationHospital Universitario Virgen Macarena
dc.page.number1390-1399
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rights.accessRightsopen access
dc.subjectacute lymphoblastic leukemia
dc.subjectchildren
dc.subjectprophylaxis
dc.subjectthrombophilia
dc.subjectthrombosis
dc.subject.meshAnticoagulants
dc.subject.meshChild
dc.subject.meshHeparin, Low-Molecular-Weight
dc.subject.meshHumans
dc.subject.meshPrecursor Cell Lymphoblastic Leukemia-Lymphoma
dc.subject.meshRetrospective Studies
dc.subject.meshRisk Factors
dc.subject.meshThrombophilia
dc.subject.meshVenous Thromboembolism
dc.titleVenous thromboembolism in pediatric patients with acute lymphoblastic leukemia under chemotherapy treatment. Risk factors and usefulness of thromboprophylaxis. Results of LAL-SEHOP-PETHEMA-2013.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number20
dspace.entity.typePublication

Files